Results 181 to 190 of about 6,613 (271)

Reducing inequities in access to postpartum hemorrhage prevention: Reframing advance distribution of misoprostol as a test case for health system responsiveness and adaptation

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 172, Issue S2, Page S26-S33, June 2026.
Abstract Advance distribution of misoprostol is an evidence‐based strategy for preventing postpartum hemorrhage (PPH) at births without skilled health personnel present. Despite its lifesaving potential, initial momentum behind this intervention has slowed over the last decade and has not been renewed since WHO released updated guidelines in 2020 or ...
Hannah Tappis   +4 more
wiley   +1 more source

Ivermectin Toxicity in Humans and Animals: Clinical Spectrum, Mechanisms, and Management

open access: yesJournal of Applied Toxicology, Volume 46, Issue 6, Page 1856-1870, June 2026.
ABSTRACT Ivermectin is a widely used macrocyclic lactone with established efficacy against a broad range of parasitic infections in humans and animals and a long‐standing reputation for clinical safety. However, increasing evidence indicates that ivermectin can produce clinically relevant toxicity under specific conditions, particularly involving the ...
Serkan Yilmaz   +3 more
wiley   +1 more source

When First‐Line Therapies Fail: Surgical Site Infections and the Declining Antimicrobial Utility in a Resource‐Limited Nation

open access: yesMicrobiologyOpen, Volume 15, Issue 3, June 2026.
In Belize, a 7‐year nationwide study reveals a sharp rise in antimicrobial resistance in surgical infections. ESBL‐producing bacteria more than doubled to > 45%, with critical treatment gaps and geographic hotspots identified. Sentinel pan‐drug‐resistant cases and a correlation between antibiotic use and resistance underscore the urgent need for ...
Innocent E. Nwachukwu   +5 more
wiley   +1 more source

Combination Versus Monotherapy in Acute Anti‐LGI1 Encephalitis: A Real‐World Dose Optimization Analysis

open access: yesNeuropsychopharmacology Reports, Volume 46, Issue 2, June 2026.
Combined IVIg and 500 mg/day IVMP achieve superior efficacy over monotherapies in anti‐LGI1 encephalitis, with optimal safety. Higher‐dose IVMP (1000 mg) accelerates response but increases adverse events, particularly in diabetic patients. Cognitive deficits persist post‐treatment, necessitating long‐term management.
Yao Tan   +6 more
wiley   +1 more source

Age‐Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy